文献速递关节外科创伤骨科

反向全肩关节置换术联合上方增强肩胛盂组件治疗Favard E1、E2和E3型肩胛盂

Reverse Total Shoulder Arthroplasty with a Superior Augmented Glenoid Component for Favard Type-E1, E2, and E3 Glenoids.
PubMed 文献 · J Bone Joint Surg Am · 2020-01-01

回顾性分析68例Favard E1、E2或E3型肩胛盂畸形肩关节炎患者,采用反向全肩关节置换术联合10°上方增强或10°上方/8°后方增强肩胛盂基板治疗,平均随访40个月。多数患者疼痛和功能获得临床意义改善,94%自评「好多了」或「好一些」,并发症发生率为7.4%。

要点

  • 94%患者自评「好多了」(73.5%)或「好一些」(20.5%)。
  • 至少88%患者超过最小临床重要差异阈值,75%超过实质性临床获益阈值。
  • 并发症5例(7.4%),包括肩峰应力骨折2例、创伤后肩胛颈骨折1例、慢性肩痛1例、无菌性肩胛盂松动1例。

核心结论

  • 伴有上方肩胛盂磨损模式(Favard E1、E2和E3型)的肩关节病可采用反向全肩关节置换术联合上方或上方/后方增强基板成功治疗。
  • 需要更长期的临床和影像学随访以确认这些有希望的短期结果是否持久。

研究设计与样本

  • 回顾性综述68例肩关节炎伴Favard E1、E2或E3型肩胛盂畸形患者,接受初次反向全肩关节置换术联合10°上方增强或10°上方/8°后方增强基板。
  • 平均随访40个月(范围24至85个月)。
  • 术前和末次随访时评估肩关节活动度和疗效评分,包括简单肩关节测试(SST)、加州大学洛杉矶分校(UCLA)评分、美国肩肘外科医师(ASES)评分、Constant评分和肩痛与残疾指数(SPADI)评分。
  • 术前和末次随访时评估X线片。
  • 采用双尾Student t检验评估术前和术后活动度及疗效指标的差异。

主要发现

  • 94%患者在末次随访时自评「好多了」(73.5%)或「好一些」(20.5%)。
  • 至少88%的患者在每个临床疗效指标和活动度方面超过最小临床重要差异(MCID)阈值。
  • 75%的患者在每个临床疗效指标和活动度方面超过实质性临床获益(SCB)阈值。
  • 报告5例并发症(发生率7.4%),包括肩峰应力骨折2例、创伤后肩胛颈骨折1例、慢性肩痛1例和无菌性肩胛盂松动1例。

关键数值与推荐

  • 94%患者自评「好多了」(73.5%)或「好一些」(20.5%)。
  • 至少88%的患者超过MCID阈值,75%的患者超过SCB阈值。
  • 并发症5例(7.4%):肩峰应力骨折2例、创伤后肩胛颈骨折1例、慢性肩痛1例、无菌性肩胛盂松动1例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更长期的临床和影像学随访以确认这些有希望的短期结果是否持久。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uncorrected superior glenoid wear in patients managed with reverse total shoulder arthroplasty (rTSA) can result in increased complications, including baseplate failure. The present study quantifies the clinical and radiographic outcomes of patients with Favard type-E1, E2, and E3 glenoid deformity who were managed with rTSA with use of a superior or superior/posterior augmented glenoid baseplate. METHODS: We retrospectively reviewed the records for 68 patients with shoulder arthritis and Favard type-E1, E2, or E3 glenoid deformity who were managed with primary rTSA and a 10° superior augmented or 10° superior/8° posterior augmented baseplate. The mean duration of follow-up was 40 months (range, 24 to 85 months). Outcomes were assessed preoperatively and at the latest follow-up with shoulder range of motion and use of outcome scores including the Simple Shoulder Test (SST), University of California Los Angeles (UCLA) score, American Shoulder and Elbow Surgeons (ASES) score, Constant score, and Shoulder Pain and Disability Index (SPADI) score. Radiographs were evaluated preoperatively and at the time of the latest follow-up. Differences in preoperative and postoperative range of motion and outcome metrics were assessed with use of a 2-tailed Student t test. RESULTS: The majority of patients experienced clinically meaningful improvements in terms of pain and function following rTSA with a superior or superior/posterior augment, with 94% of patients rating themselves as "much better" (73.5%) or "better" (20.5%) at the time of the latest follow-up. At least 88% of the patients exceeded the minimum clinically important difference (MCID) threshold, and 75% of patients exceeded the substantial clinical benefit (SCB) threshold, for each of the clinical outcome metrics and range of motion. Five complications were reported (prevalence, 7.4%), including acromial stress fracture (2 patients), posttraumatic scapular neck fracture (1 patient), chronic shoulder pain (1 patient), and aseptic glenoid loosening (1 patient). CONCLUSIONS: The present short-term clinical and radiographic study demonstrated that shoulder arthropathy with superior glenoid wear patterns (Favard types E1, E2, and E3) can be successfully treated with rTSA with a superior or superior/posterior augmented baseplate. Longer-term clinical and radiographic follow-up is necessary to confirm that these promising short-term results are durable. LEVEL OF EVIDENCE: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Liuzza L, Mai DH, Grey S, et al. Reverse Total Shoulder Arthroplasty with a Superior Augmented Glenoid Component for Favard Type-E1, E2, and E3 Glenoids. J Bone Joint Surg Am. 2020. PMID: 32740263. doi:10.2106/JBJS.19.00946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。